The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Toxicities associated with TKI maintenance therapy following allo-HSCT in patients with Ph+ ALL
|
A retrospective analysis assessed the toxicities associated with TKI maintenance therapy following allo-HSCT in 185 adult patients with Ph+ ALL.1 Patients were divided into three groups based on the first TKI they received post-allo-HSCT: imatinib (n = 50), 2G-TKI (n = 118), or ponatinib (n = 17). Results from this analysis were published in the American Journal of Hematology by Othman et al.1
|
| Key learnings |
|
TKI maintenance therapy post-allo-HSCT in patients with Ph+ ALL was associated with significant toxicities, which lead to dose reductions, interruptions, and discontinuations in 41.6%, 65.4%, and 35.7% of patients, respectively. |
|
The most common toxicities leading to TKI discontinuation included gastrointestinal intolerance (16.0%), cytopenias (6.0%), and fluid retention (6.0%). |
|
Ponatinib was associated with lower dose interruptions (47.1% vs 54.0% vs 72.9%; p = 0.01) and discontinuations (17.1% vs 38.0% vs 51.7%; p = 0.02) vs imatinib and 2G-TKIs, respectively. Ponatinib was also associated with a longer duration of maintenance therapy vs 2G-TKIs (576.0 days vs 254.5 days; p = 0.02). |
|
The 5-year OS and PFS rates for the total population were 79% and 71%, respectively, with no differences based on TKI selection. |
|
These findings highlight the significant toxicities associated with TKI maintenance therapy post-allo-HSCT in patients with Ph+ ALL. TKIs with fewer toxicities, such as ponatinib, or other novel therapies may improve outcomes for this patient population. |
Abbreviations: 2G, second-generation; ALL, acute lymphoblastic leukemia; allo-HSCT, allogeneic hematopoietic stem cell transplantation; OS, overall survival; PFS, progression-free survival; Ph+, Philadelphia-positive; TKI, tyrosine kinase inhibitor.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with T-cell acute lymphoblastic leukemia do you see in a year?
